In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Indaptus Therapeutics (INDP – Research Report), with a price target of $8.00.
Jason McCarthy’s rating is based on a combination of factors that highlight the potential of Indaptus Therapeutics’ Decoy20 platform. The innovative approach of using non-pathogenic bacteria to activate both the innate and adaptive immune systems is a significant advancement in oncology. The technology is an evolution of historical cancer treatments but with reduced toxicity, which positions it as a promising therapy. Moreover, the recent positive data presented at the AACR conference demonstrates Decoy20’s ability to engage multiple immune cell types, enhancing its credibility as an effective cancer treatment.
Furthermore, the progression to multi-dosing in the Phase 1 study, following encouraging results from the initial cohorts, signifies a critical step in the drug’s development process. The safety and immune response indicators are promising, and the potential to determine the maximum tolerated dose and recommended Phase 2 dose offers a clear pathway forward for clinical development. This strategic clinical advancement, coupled with the platform’s potential for broad immune response activation and synergy with other treatments, underpins McCarthy’s optimistic Buy rating for Indaptus Therapeutics.
INDP’s price has also changed slightly for the past six months – from $2.500 to $2.750, which is a 10.0% increase.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Indaptus Therapeutics (INDP) Company Description:
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company engaging in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvi Joseph in 2000 and is headquartered in Jerusalem, Israel.
Read More on INDP:
- Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting
- Indaptus presents mechanism of action data at AACR for Decoy platform
- Indaptus Therapeutics previews presentation of mechanism of action data
- Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting
- Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
